Celgene To Pursue Revlimid Combination Use For Melanoma After Halting Monotherapy Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Ongoing Phase III in multiple myeloma will not be derailed by the discontinuation of melanoma trials for lack of efficacy, company says. Planned earlier-phase malignant melanoma trials will test Revlimid in combination with dacarbazine, temozolomide.